BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 17301095)

  • 1. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis.
    Chaudhary NI; Roth GJ; Hilberg F; Müller-Quernheim J; Prasse A; Zissel G; Schnapp A; Park JE
    Eur Respir J; 2007 May; 29(5):976-85. PubMed ID: 17301095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imatinib mesylate attenuates fibrosis in coxsackievirus b3-induced chronic myocarditis.
    Leipner C; Grün K; Müller A; Buchdunger E; Borsi L; Kosmehl H; Berndt A; Janik T; Uecker A; Kiehntopf M; Böhmer FD
    Cardiovasc Res; 2008 Jul; 79(1):118-26. PubMed ID: 18326555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.
    Distler JH; Jüngel A; Huber LC; Schulze-Horsel U; Zwerina J; Gay RE; Michel BA; Hauser T; Schett G; Gay S; Distler O
    Arthritis Rheum; 2007 Jan; 56(1):311-22. PubMed ID: 17195235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Influence of Feixian Formula on serum transforming growth factor-beta1 and platelet-derived growth factor in rats with bleomycin-induced pulmonary fibrosis].
    Zhang W; Jiang LD; Zhang XM; Wu JJ; Deng Y; Lu XF
    Zhong Xi Yi Jie He Xue Bao; 2008 Jun; 6(6):595-9. PubMed ID: 18559237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VEGFR-2 antagonist SU5416 attenuates bleomycin-induced pulmonary fibrosis in mice.
    Ou XM; Li WC; Liu DS; Li YP; Wen FQ; Feng YL; Zhang SF; Huang XY; Wang T; Wang K; Wang X; Chen L
    Int Immunopharmacol; 2009 Jan; 9(1):70-9. PubMed ID: 18976720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis.
    Wollin L; Maillet I; Quesniaux V; Holweg A; Ryffel B
    J Pharmacol Exp Ther; 2014 May; 349(2):209-20. PubMed ID: 24556663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of activin receptor-like kinase 5 attenuates bleomycin-induced pulmonary fibrosis.
    Higashiyama H; Yoshimoto D; Kaise T; Matsubara S; Fujiwara M; Kikkawa H; Asano S; Kinoshita M
    Exp Mol Pathol; 2007 Aug; 83(1):39-46. PubMed ID: 17274978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib mesylate attenuates myocardial remodeling through inhibition of platelet-derived growth factor and transforming growth factor activation in a rat model of hypertension.
    Jang SW; Ihm SH; Choo EH; Kim OR; Chang K; Park CS; Kim HY; Seung KB
    Hypertension; 2014 Jun; 63(6):1228-34. PubMed ID: 24591339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis.
    Daniels CE; Wilkes MC; Edens M; Kottom TJ; Murphy SJ; Limper AH; Leof EB
    J Clin Invest; 2004 Nov; 114(9):1308-16. PubMed ID: 15520863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sunitinib, a Small-Molecule Kinase Inhibitor, Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice.
    Huang X; Wang W; Yuan H; Sun J; Li L; Wu X; Luo J; Gu Y
    Tohoku J Exp Med; 2016 Aug; 239(4):251-61. PubMed ID: 27439438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the protein kinase inhibitor, imatinib mesylate, on epithelial/mesenchymal phenotypes: implications for treatment of fibrotic diseases.
    Vittal R; Zhang H; Han MK; Moore BB; Horowitz JC; Thannickal VJ
    J Pharmacol Exp Ther; 2007 Apr; 321(1):35-44. PubMed ID: 17218487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic effects of imatinib and carboplatin on VEGF, PDGF and PDGF-Rα/ß expression in squamous cell carcinoma of the head and neck in vitro.
    Schultz JD; Rotunno S; Riedel F; Anders C; Erben P; Hofheinz RD; Faber A; Thorn C; Sommer JU; Hörmann K; Sauter A
    Int J Oncol; 2011 Apr; 38(4):1001-12. PubMed ID: 21249316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antifibrotic effects of focal adhesion kinase inhibitor in bleomycin-induced pulmonary fibrosis in mice.
    Kinoshita K; Aono Y; Azuma M; Kishi J; Takezaki A; Kishi M; Makino H; Okazaki H; Uehara H; Izumi K; Sone S; Nishioka Y
    Am J Respir Cell Mol Biol; 2013 Oct; 49(4):536-43. PubMed ID: 23642017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib mesylate inhibits in vitro and ex vivo biological responses related to vascular occlusion in giant cell arteritis.
    Lozano E; Segarra M; García-Martínez A; Hernández-Rodríguez J; Cid MC
    Ann Rheum Dis; 2008 Nov; 67(11):1581-8. PubMed ID: 17584806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of nilotinib on bleomycin-induced acute lung injury and pulmonary fibrosis in mice.
    Rhee CK; Lee SH; Yoon HK; Kim SC; Lee SY; Kwon SS; Kim YK; Kim KH; Kim TJ; Kim JW
    Respiration; 2011; 82(3):273-87. PubMed ID: 21659722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of platelet-derived growth factor/platelet-derived growth factor receptor axis in the trafficking of circulating fibrocytes in pulmonary fibrosis.
    Aono Y; Kishi M; Yokota Y; Azuma M; Kinoshita K; Takezaki A; Sato S; Kawano H; Kishi J; Goto H; Uehara H; Izumi K; Nishioka Y
    Am J Respir Cell Mol Biol; 2014 Dec; 51(6):793-801. PubMed ID: 24885373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amelioration of liver fibrogenesis by dual inhibition of PDGF and TGF-beta with a combination of imatinib mesylate and ACE inhibitor in rats.
    Yoshiji H; Kuriyama S; Noguchi R; Ikenaka Y; Yoshii J; Yanase K; Namisaki T; Kitade M; Yamazaki M; Asada K; Akahane T; Tsujimoto T; Uemura M; Fukui H
    Int J Mol Med; 2006 May; 17(5):899-904. PubMed ID: 16596278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model.
    Chaudhary NI; Schnapp A; Park JE
    Am J Respir Crit Care Med; 2006 Apr; 173(7):769-76. PubMed ID: 16415276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
    Hilberg F; Roth GJ; Krssak M; Kautschitsch S; Sommergruber W; Tontsch-Grunt U; Garin-Chesa P; Bader G; Zoephel A; Quant J; Heckel A; Rettig WJ
    Cancer Res; 2008 Jun; 68(12):4774-82. PubMed ID: 18559524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined inhibition of vascular endothelial growth factor (VEGF), fibroblast growth factor and platelet-derived growth factor, but not inhibition of VEGF alone, effectively suppresses angiogenesis and vessel maturation in endometriotic lesions.
    Laschke MW; Elitzsch A; Vollmar B; Vajkoczy P; Menger MD
    Hum Reprod; 2006 Jan; 21(1):262-8. PubMed ID: 16172144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.